Early indications are a new swine flu vaccine is safe and is on track to be made available to the public by mid-October, US health officials said.
"There are no red flags regarding safety," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, yesterday noting that a series of clinical trials were being conducted on the vaccine with results due out between mid September and late October.
Adult volunteers participated in the first of five trials starting on August 7, and only reported arm swelling or redness where they received the injection.
Encouraged by the results, health officials went ahead this week with vaccine trials on children aged six months to 17 years, Fauci told reporters.
Additional experiments on about 120 pregnant women -- who are particularly at risk of infection from the influenza A(H1N1) virus and are high on the federal government's priority list for vaccines -- are to begin in September.
Officials expect that between 4,500 and 4,600 people will eventually take part in the vaccine studies.
Between 45 and 52 million doses of the vaccine are expected to be available by mid-October, said Jay Butler, who heads the H1N1 Vaccine Task Force of the US Centers for Disease Control and Prevention (CDC).
The CDC, which had made plans to distribute the vaccine once available, has issued its final recommendations for which groups of people should receive the shot.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
